Dr. Drazer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
Chicago, IL 60637Phone+1 773-702-1000
Summary
- Dr. Michael Drazer is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from University of Chicago Division of the Biological Sciences The Pritzker School of Medicine and has been in practice 5 years. He is experienced in bone marrow failure syndromes, prostate cancer screening, and leukemia. He has more than 20 publications and over 500 citings.
Education & Training
University of ChicagoPhD, Human Genetics, 2017 - 2021
University of ChicagoFellowship, Hematology and Medical Oncology, 2015 - 2018- University of ChicagoResidency, Internal Medicine, 2012 - 2015
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2012
Certifications & Licensure
IL State Medical License 2015 - 2026
IN State Medical License 2020 - 2025
MI State Medical License 2022 - 2025
ID State Medical License 2020 - 2024
TN State Medical License 2022 - 2024
VA State Medical License 2022 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.Gregory W Roloff, Satyajit Kosuri, Mariam T Nawas, Adam S DuVall, Anand A Patel
Haematologica. 2024-11-01 - 1 citationsGerm line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition.Jiarna R Zerella, Claire C Homan, Peer Arts, Xuzhu Lin, Sam J Spinelli
Blood. 2024-10-24 - FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect.Henry W Raeder, Michael W Drazer
Clinical Cancer Research. 2024-07-15
Press Mentions
ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
